Viridian TherapeuticsVRDN
Recorded

Viridian Therapeutics Jefferies Global Healthcare Conference

Review the key takeaways and the transcript of this earnings call.

Period 0Duration26 minParticipants3

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Faisal KhurshidManaging Director and Senior Biotech Equity Research Analyst

All for being here with us at the Jefferies London Global Healthcare Conference. My name is Faisal Khurshid, Senior Biotech Analyst at Jefferies. We are really pleased to have with us today the management team of Viridian Therapeutics. So we have Steve Mahoney, CEO, Shan Wu, CBO. Can I just ask you guys to briefly introduce the company? Then we got a lot of interesting stuff to get into.

Steve MahoneyCEO

Yeah, sure. Thanks everyone for coming today. Yes, we have a lot going on at the company, so I will try to do the overview very quickly so we can get to the questions. We just recently launched our first product, LUMVOA. We reported our first quarter numbers, which were very good, very exciting in terms of the execution. We did $24.7 million in revenue for the first quarter. We had over 100 patients on drug as of the September 30th date. So really encouraging. We are really excited about the start that we got. I am sure we will get into more details as well, so on this. Off to a great start. It is early, it is a first quarter of launch, but a lot of good signs. We also have our next-generation product that is coming in behind it.

Steve MahoneyCEO

We have our BLA that we will submit for the subQ version for IGF-1R, which we had two positive phase III readouts earlier this year. So really exciting to be able to put IGF-1R inhibition into an autoinjector pen for really easy self at-home administration. So we are looking forward to that BLA, Q1 2027, we are filing. We also have our TSHR program, which fits into our thyroid autoimmunity franchise with respect to a TSHR program that is going into the clinic starting this year, is our expectation. So we are moving forward there as well. That is an exciting program, big opportunity in the Graves population. Also has applicability possibly in TED, although IGF-1R sets the bar pretty high there. We are looking forward to that. We think that is a complementary program for our franchise. We also just recently put out data for our FcRn franchise.

Steve MahoneyCEO

We had two FcRn assets, VRDN-006 and VRDN-008. VRDN-006 was the Fc fragment, very much like the VYVGART asset. Then we had our VRDN-008 program, which is half-life extended. So what we recently just put out was potentially best-in-class FcRn profile, because we can get every eight-week dosing. We saw 74% peak IgG reduction. We saw sustained IgG suppression. We saw sustained IgG suppression out to eight weeks, which is a game-changer for patients. Obviously, albumin sparing, you needed to see that as well. So we are really happy with the thyroid eye disease franchise, the Graves program that is advancing, and then obviously FcRn to potentially have the best profile in FcRn would be really exciting.

Faisal KhurshidManaging Director and Senior Biotech Equity Research Analyst

Got it. Awesome. Thank you for the intro. You guys have a lot going on right now, so there is a lot to cover. Let us start with the LUMVOA launch. As I think high level about the TED market, TEPEZZA is doing what looks to be a pretty sustainable $2 billion per year revenue run rate. You guys, in my opinion, just simply have a better product. It is at least as good on efficacy, roughly comparable in safety, and much easier to give. In theory, if you just kind of take a step back and before you even do any doc calls, before you even do any surveys, you should take over TEPEZZA, is what I think. How fast should that happen?

Steve MahoneyCEO

Yeah, obviously timelines on that, we do think it is going to get fast to peak. We do think the market is conducive to that. It is a new start market. We do not switch patients off of the current other available product, TEPEZZA. So it does lend itself to a fast to peak. What fast to peak means in reality needs to be seen. Again, we are very happy with the first quarter of launch. I think that was a function of the product profile, to your point. I think given the fact that we had Breakthrough Therapy Designation, we had Priority Review designation for that drug, our application for that was on the basis of the rapid onset of treatment effect. So we were seeing people, a majority of people were getting proptosis response after just one infusion, and that had not been seen before.

Steve MahoneyCEO

We also saw incredible diplopia benefit in the chronic patient population of thyroid eye disease. This is people that were not only responding on the Gorman score, but they are actually achieving complete resolution at a rate that we had not seen before either. Our drug was designed to be a full antagonist. TEPEZZA is a partial antagonist. So we designed it that way so we could dose less in terms of the volume that we are dosing, but also the number of infusions, which ultimately comes into the fact that we are dosing for a five-infusion course versus the eight-infusion course for TEPEZZA. Those three elements, rapid onset of treatment, the diplopia, and the shorter course of treatment are all really good benefits of the profile that have lent itself to what we have seen so far, but it is still early.

Faisal KhurshidManaging Director and Senior Biotech Equity Research Analyst

Got it. Yeah. And sorry, Steve, I know I asked you the leading question to lead all leading questions. But in terms of the metrics that you guys disclosed, so you disclosed the $24.7 million in your first full quarter, which is an awesome result. You gave us the metric that you have more than 100 patients on therapy, so that basically tells us that we know this is not stocking, this is actually infusions. But you did not give us as much in the sense of leading indicators, like prescriptions or things like that. How should we think about the trajectory and kind of the pace of growth over the next few quarters?

Steve MahoneyCEO

Yeah. Well, maybe I will start, and Sean can jump in. I think the most concrete metrics that you are going to get is to answering the question as to whether the first three months of your launch are going well is your revenues and whether you are getting patients on drug. So, those are the numbers that we provided. So we think those are the most concrete measurements that tell you whether we are doing well on the execution side. We do say that it is still early, that we have more work to do. When we start on day one of launch, you do not have any policy coverage, so you have to work through the payers in order to advance that and to get even more patients on therapy.

Steve MahoneyCEO

I think right now we are telling people that we feel really good about how things are going on the execution side, our field engagement, our market access, and then ultimately demand. So I think we answered those three questions.

Faisal KhurshidManaging Director and Senior Biotech Equity Research Analyst

Got it. Then in terms of, like, you are characterizing, you said many times that you are very pleased with the progress. If we were to just kind of find Steve from six months ago and ask him, blast from the past, would you say the launch so far has gone better than what you would have hoped six months ago? Like, are you tracking ahead of what you wanted to deliver on?

Steve MahoneyCEO

Yeah. I mean, I think we have been clear that it certainly exceeded our expectations, but then when I do look back, so thank you for that, formal question. When we do look back, I think it is pretty obvious as to why we executed so well. We hired our sales team early. Although they could not be in the field talking about the product, they could go out and profile accounts and make relationships so that they were able to hit the ground running on day one of launch. We also took advantage of the preapproval information exchange capability that you have when you can go out and show your profile to payers. Payers are familiar with IGF-1R as a mechanism. They are familiar with TEPEZZA. They are familiar with our data because we had done quite a bit of payer research prior to that.

Steve MahoneyCEO

The nice part there was that they indicated to us that if we provided parity pricing, that they would provide parity coverage. TEPEZZA had done a lot of legwork over the years. It took them close to five years to get to 85% of covered lives, which is a great footprint for us to step into. We are not there yet on coverage because even when you get approved, you still have to work through each payer's timelines, with P&T committees and things like that. Still more work to do there. I think we indicated on the call that we had achieved about 30% covered lives by the end of September.

Steve MahoneyCEO

When we look back, that legwork, hiring the team early, getting in front of payers early, we had a lot of high TEPEZZA prescribers that were PIs in our trial, so our clinical trial infrastructure was helpful in terms of familiarity with the drug. I think all those things helped.

Shan WuChief Business Officer

In terms of execution as well, I also add that the commercial strategy here is a simple one. We are not trying to reinvent the wheel. There are about 2,000 prescribers who write more than 80% of IGF-1R scripts, and so that is our focus for the LUMVOA IV launch. Even in August with Q2 earnings, a month in, so just four weeks, we talked about having already engaged with over 95% of those core prescribers. We were able to get out the door with our field force within 24 hours. Within launch, our field was talking about LUMVOA with these physicians. A lot of that comes from the preapproval groundwork that we laid with both the field as well as with market access.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.

View the full transcript with Pro

Other earnings calls that day

View calls from this day